{"id":"W4380323763","doi":"10.1186/s13058-023-01649-w","title":"XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Medicine; Everolimus; Internal medicine; Breast cancer; Hazard ratio; Tolerability; Placebo; Oncology; Metastatic breast cancer; Clinical endpoint; Aromatase inhibitor; Cancer; Clinical trial; Adverse effect; Confidence interval; Aromatase; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002138811,0.002218738,0.003084152,0.0005911055,0.0004751646,0.001150261,0.001139841,0.002287531,0.008758067],"category_scores_gemma":[0.001954654,0.001053351,0.001704618,0.0004223885,0.001784084,0.00127696,0.0005691609,0.003015395,0.001315513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008751192,"about_ca_system_score_gemma":0.001372288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006585289,"about_ca_topic_score_gemma":0.001521572,"domain_scores_codex":[0.9991933,0.0004619376,0.00004315917,0.0001346797,0.00004301928,0.0001240655],"domain_scores_gemma":[0.9990448,0.0002813028,0.0002232483,0.00006861234,0.00005199357,0.0003298626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830287,0.006764663,0.0001569343,0.0003404571,0.000225549,0.00002396604,0.00003662186,0.0002409165,0.002675048,0.00008693043,0.0003520313,0.006068187],"study_design_scores_gemma":[0.9310283,0.06760209,0.0003977015,0.00001328183,0.00009127879,0.00002086106,0.000008908998,0.0001990069,0.0002742345,0.00007366921,0.0002824996,0.000008219072],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.976705,0.004239185,0.001101024,0.0008241517,0.0009487625,0.01178998,0.0014952,0.0002346058,0.002661987],"genre_scores_gemma":[0.9732572,0.002641281,0.002279639,0.001177983,0.0006782345,0.01229906,0.001474202,0.00004368577,0.006148699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008758067,"threshold_uncertainty_score":0.02929866,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05492335571633707,"score_gpt":0.3966304399903068,"score_spread":0.3417070842739697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}